Roozbeh Eskandari1, Arsen Mamakhanyan1, Michelle Saoi2, Kristin L Granlund1, Justin Cross2, Craig B Thompson3, and Kayvan Rahimi Keshari1,4
1Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 2Memorial Sloan Kettering Cancer Center, New York, NY, United States, 3Cancer Biology & Genetics Program Share, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 4Radiology, Memorial Sloan Kettering, New York, NY, United States
1Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 2Memorial Sloan Kettering Cancer Center, New York, NY, United States, 3Cancer Biology & Genetics Program Share, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 4Radiology, Memorial Sloan Kettering, New York, NY, United States
We developed a custom-synthesized compound, [5-13C,4,4-2H2,5-15N]-L-Glutamine, as a hyperpolarized MRI probe for glutaminase activity. We were able to detect in vivo conversion of hyperpolarized glutamine to glutamate in murine model of PDAC.
Conversion of [5-13C,4-2H2,5-15N]-L-Glutamine to [5-13C,4-2H2]-L-Glutamate with glutaminase in tumor. Red, orange, blue represent sites of 13C, 2H and 15N enrichment, respectively.
A T2-weighted 1H MRI of mouse, with tumor (right) highlighted as regions of sagittal slab B Dynamic of conversion of glutamine to glutamate in the tumor with vehicle. C Dynamic of conversion of glutamine to glutamate in the tumor with glutaminase inhibitor CB-839
